Skip to main content

IBA launches Cyclone® iKure, a cyclotron designed for industrial scale Astatine-211 production

Written by Customer Service on . Posted in Public Companies.

Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today launches Cyclone® iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs.

Targeted alpha therapy is emerging as an important area of development in precision oncology. Alpha-emitting isotopes deliver highly concentrated radiation over a very short distance, destroying cancer cells with remarkable precision with limited exposure to surrounding healthy tissue1. Among alpha emitters, At-211 is attracting attention for its chemical properties and half-life2. Yet translating clinical promises into routine patient care has been held back by a fundamental challenge: establishing reliable production infrastructure at scale. With Cyclone® iKure, IBA aims to address this production challenge.

Cyclone® iKure has been designed specifically for At-211-isotope workflows. It has been engineered to deliver consistent, high-yield At-211 output at production scale. Automated processes simplify daily operations and minimize operator radiation exposure, while a compact footprint allows the system to fit within limited infrastructure, reducing site preparation complexity and cost. The system is designed to meet applicable CE marking requirements, and regulatory compliance.

Cyclone® iKure draws on IBA’s four decades of cyclotron engineering expertise, the same foundation behind the Cyclone® KIUBE, Cyclone® IKON and Cyclone® KEY platforms that serve radiopharmaceutical producers and hospitals worldwide. With this launch, IBA extends its cyclotron portfolio from diagnostic PET & SPECT imaging to therapeutic alpha-isotope production.

“Targeted alpha therapy has significant clinical potential, but realizing it at scale depends on reliable and scalable production infrastructure,” said Charles Kumps, President of IBA RadioPharma Solutions. “With Cyclone® iKure, we are bringing to the alpha-therapy space the precision and dependability that IBA is known for. Designed for routine At-211 production, it is built to help radiopharma innovators and clinicians move from early-stage programs to routine clinical application — and to make targeted alpha therapies accessible to the patients who need them.”

The launch of Cyclone® iKure reinforces IBA’s commitment to accelerating the bench-to-bedside transition of At-211-labeled drugs. IBA’s strategy rests on three pillars: a purpose-built product, with Cyclone® iKure enabling routine, industrial-scale At-211 production; ecosystem leadership, through its role as industry co-leader in the ACCELERATE.EU initiative to build the complete European At-211 value chain; and production capacity, through its strategic partnership with Framatome to explore a transatlantic At-211 production network.

***Ends***

About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

For further information, please contact:
Nathalie van Ypersele
Head of Communication and Sustainability
+32 10 475 890
communication@iba-group.com

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

1 Albertsson P et al; Frontiers in Med (2023),9, 1076210: doi:10.3389/fmed.2022.1076210. 

2 Lindegren et al. EJNMMI Radioph. and Chem. (2026) 11, 15 doi:10.1186/s41181-026-00428-0

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.